亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Anti-ADAM10 antibody (8C7) for cancer therapy

總結: Novel mAbs that bind a unique epitope on a cancer-associated form of the ADAM10 metalloprotease. Inhibiting ADAM10 blocks activation of receptors linked to the ‘stem cell niche’ and depletes cancer stem cells resistant to chemotherapeutic treatments. The lead mAb is potentially useful as ‘cancer specific’ single agent, drug conjugate and/or combination therapy.

技術優勢: - Proof of concept data shows single agent and combination efficacy in vivo
- Potential use as naked and/or functionalised (ADC) therapeutic
- Targets ‘stem cell niche’ to sensitise chemoresistant tumours

技術應用: The development of tumour-selective ADAM10 inhibitors offers an improved approach to treating aggressive cancers such as Her2+ breast cancer, and preventing chemoresistance, without the safety issues commonly associated with non-selective MMP inhibition.

詳細技術說明: 8C7 (Lead mAb) preferentially binds active ADAM10 at a conformation-specific epitope prevalent in tumours but not in normal tissue. Preclinical studies showed that 8C7 inhibits ADAM10- mediated cleavage and activation of Notch and RTK signalling. In colorectal cancer (CRC) xenograft tumors, 8C7 preferentially targets tumors, especially CD133+ stem cells, and inhibits tumor growth as well as the expression of key ADAM10 targets. In combination with irinotecan (a topoisomerase I inhibitor used clinically for CRC), 8C7 prevents tumour relapse with a marked reduction in CD133+ stem cells in remaining tumours. Fully human mAb 8C7 is in development and further combination studies are underway.

其他: Monash seeks a partner to clinically develop and translate this opportunity.

欲了解更多信息，請點擊這裡